Ireland· IE-PA-EU/1/13/884/001-004
Invokana 100 mg film-coated tablets
A canagliflozin product containing canagliflozin, registered in Ireland by Janssen-Cilag International NV. The same ATC class is registered in 15 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Canagliflozin is registered in 15 of 19 countries.
Countries holding a registration under ATC A10BK02 (canagliflozin), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 9 of them publish a price we can compare per daily dose
Canagliflozin · ATC A10BK02
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of canagliflozin costs, country by country.
Normalised to the WHO defined daily dose (0.2 g), the median price runs from $2.52 in Switzerland to $25.50 in United States — a ×10 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Canagliflozin · price per daily dose (0.2 g)
USD · FX 28 Sept 2026
- US United States$25.50 (acquisition cost)
- IT Italy$3.76
- CH Switzerland$2.52
The record
At a glance
HPRA (Ireland)- Active substance
- Canagliflozin
- Manufacturer
- Janssen-Cilag International NV
- Country
- Ireland (IE)
- ATC code
- A10BK02
- ATC class
- Canagliflozin
- Defined daily dose
- 0.2 g, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/13/884/001-004
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
429 interactions on record for canagliflozin.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Canagliflozin · interactions on record
429 records
- 1 severe
- 388 moderate
- 40 minor
Most severe, free to view
- SucralfateA02BX02moderate
- PapaverineA03AD01moderate
- ThiethylperazinA04AB03moderate
- TriflupromazinA04AD06moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Canagliflozin in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaINVOKANAJanssen-Cilag International N.V., Beerse
- United StatesINVOKANAA-S Medication Solutions
- SpainCANAGLIFLOZINA TEVA 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGTeva B.V.
- FinlandCanagliflozin ratiopharmTeva B.V.
- SwitzerlandInvokana
- PolandInvokanaJanssen-Cilag International N.V.
- SwedenInvokana 100 mg Filmdragerad tablettJanssen-Cilag International NV
- IcelandInvokanaJanssen-Cilag International NV*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Invokana
- Liechtenstein · Invokana
- Norway · Invokana
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d86a6b71-86ee-4084-8872-a140f4bc73bd GET /v1/drugs/d86a6b71-86ee-4084-8872-a140f4bc73bd?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"A10BK",
"A10BK02"
],
"strength": null,
"pa_number": "EU/1/13/884/001-004",
"substances": [
"Canagliflozin"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": null,
"dispensing_status": "Product subject to prescription which may be renewed (B)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about canagliflozin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.